Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) recently announced that the European Medicines Agency (EMA) has approved Perjeta (pertuzumab) as a combination therapy for the treatment of adults with previously untreated HER2-positive metastatic breast cancer (mBC).

HER2-positive cancer is an aggressive form of breast cancer, which is the most common cancer among women.

The EU’s decision was based on positive results from the phase III CLEOPATRA study. The results demonstrated that the risk of death was reduced by 34% in patients who received the combination of Perjeta, Herceptin and chemotherapy in comparison to patients receiving the combination of Herceptin and chemotherapy alone.

The approval does not come as a surprise since in Dec 2012 the Committee for Medicinal Products for Human Use (CHMP) of the EMA had recommended the approval of Perjeta for the indication.

We note that the US Food and Drug Administration (FDA) approved Perjeta plus Herceptin and docetaxel chemotherapy for treating HER2-positive mBC in patients in Jun 2012.

Roche also received approval for Perjeta in Switzerland and Mexico in Aug 2012 and Sep 2012, respectively. Moreover, Roche expects to get Perjeta approved in more countries in 2013.

We remind investors that in Feb 2013, the FDA approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of patients suffering from HER2-positive mBC.

We believe the approvals of Perjeta and Kadcyla has strengthened the company’s HER2-franchise considerably. Roche expects Perjeta and Kadcyla to positively impact results in 2013

Roche currently carries a Zacks Rank #4 (Sell). Pharma stocks, which currently look well placed, include Mylan Inc. (MYL - Analyst Report), Shire plc (SHPG) and Furiex Pharmaceuticals . All three stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%